Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio January 10, 2024
Merck to Acquire Harpoon Therapeutics, including HPN328 in certain patients with small cell lung cancer and neuroendocrine tumors January 10, 2024
FDA Issued New Postmarketing Requirement on Supplemental NDA seeking full approval of LUMAKRAS® (sotorasib) January 10, 2024
FAILED TRIAL: CARMEN-LC03 trial did not meet dual primary endpoint of improving PFS; tusamitamab ravtansine clinical development program to be discontinued January 4, 2024
Positive Immune Response and Survival Data reported in Completed Ph 1 Study of Galinpepimut-S + Opdivo in Advanced Malignant Pleural Mesothelioma January 4, 2024
Supplemental BLA and NDA submitted for RYBREVANT® (amivantamab-vmjw) + Lazertinib for the Treatment of Patients with EGFR-Mutated NSCLC January 4, 2024
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC January 4, 2024
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1 December 19, 2023
Ph 3 INTerpath-002 Study of V940 (mRNA-4157) – KEYTRUDA combination for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC December 19, 2023
Application submitted to the EMA for RYBREVANT + Chemo for the Treatment of Adult Patients with Advanced EGFR-Mutated NSCLC After Failure of Prior Therapy December 11, 2023
KEYLYNK-008 Trial of KEYTRUDA + LYNPARZA for Patients With Metastatic Squamous NSCLC to Stop for Futility December 11, 2023
Interim Data Presented from Two Ongoing Ph 2 Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation December 11, 2023
Findings from Ph 2 KeyVibe-002 Trial of Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with mNSCLC Announced December 11, 2023
Subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types December 4, 2023
Supplemental BLA submitted to FDA Seeking Approval of RYBREVANT + Chemo in EGFRm NSCLC Patients Who Progressed on or after Osimertinib December 4, 2023
FDA Approves Augtyro™ (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive NSCLC December 4, 2023
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs October 25, 2023
Tagrisso plus chemo granted Priority Review in the US for patients with EGFR-mutated advanced NSCLC October 25, 2023
FDA Approves KEYTRUDA for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemo as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery October 25, 2023
European Commission Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemo October 25, 2023
